Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM
| Authors |
Martin Stenson Anders Pedersen Sverker Hasselblom Herman Nilsson-Ehle B Göran Karlsson Rui Pinto Per-Ola Andersson |
|---|---|
| Published in | Leukemia & lymphoma |
| Volume | 57 |
| Issue | 8 |
| Pages | 1814-1822 |
| ISSN | 1029-2403 |
| Publication year | 2016 |
| Published at |
Swedish NMR Centre at Göteborg University Institute of Medicine Institute of Medicine, Department of Internal Medicine and Clinical Nutrition |
| Pages | 1814-1822 |
| Language | en |
| Links |
dx.doi.org/10.3109/10428194.2016.11... |
| Subject categories | Biological Sciences, Hematology |
The prognosis for diffuse large B-cell lymphoma (DLBCL) patients with early relapse or refractory disease is dismal. To determine if clinical outcome correlated to diverse serum metabolomic profiles, we used (1)H nuclear magnetic resonance (NMR) spectroscopy and compared two groups of DLBCL patients treated with immunochemotherapy: i) refractory/early relapse (REF/REL; n=27) and ii) long-term progression-free (CURED; n = 60). A supervised multivariate analysis showed a separation between the groups. Among discriminating metabolites higher in the REF/REL group were the amino acids lysine and arginine, the degradation product cadaverine and a compound in oxidative stress (2-hydroxybutyrate). In contrast, the amino acids aspartate, valine and ornithine, and a metabolite in the glutathione cycle, pyroglutamate, were higher in CURED patients. Together, our data indicate that NMR-based serum metabolomics can identify a signature for DLBCL patients with high-risk of failing immunochemotherapy, prompting for larger validating studies which could lead to more individualized treatment of this disease.
© UNIVERSITY OF GOTHENBURG • Sweden • Box 100 • SE-405 30 Gothenburg
Phone: +46 31 786 0000 • Contact • Organisation number: 202100-3153
About the website
Facebook
Twitter
Instagram
Youtube
Weibo